Peer Reviewed


Document Type


Publication Date



Cystic fibrosis, drug cytotoxicity, lung fibrosis


This work, including the efforts of Marc Devocelle, was funded by Science Foundation Ireland (SFI) (06/RFP/CHO024/602 EC07). This work, including the efforts of Éanna Forde, was funded by Society for General Microbiology (SGM) (RVG14/15). This work, including the efforts of Éanna Forde, was funded by Higher Education Authority (HEA) (BioAT).


Copyright © American Society for Microbiology, Antimicrobial agents and chemotherapy.2016;60(5):2813-21. doi: 10.1128/AAC.00157-16


There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial agents for the treatment of many conditions, including cystic fibrosis (CF). The challenging conditions of the CF patient lung require robust AMPs that are active in an environment of high proteolytic activity but that also have low cytotoxicity and immunogenicity. Previously, we developed prodrugs of AMPs that limited the cytotoxic effects of AMP treatment by rendering the antimicrobial activity dependent on the host enzyme neutrophil elastase (NE). However, cytotoxicity remained an issue. Here, we describe the further optimization of the AMP prodrug (pro-AMP) model for CF to produce pro-WMR, a peptide with greatly reduced cytotoxicity (50% inhibitory concentration against CFBE41o- cells, >300 μM) compared to that of the previous group of pro-AMPs. The bactericidal activity of pro-WMR was increased in NE-rich bronchoalveolar lavage (BAL) fluid from CF patients (range, 8.4% ± 6.9% alone to 91.5% ± 5.8% with BAL fluid; P = 0.0004), an activity differential greater than that of previous pro-AMPs. In a murine model of lung delivery, the pro-AMP modification reduced host toxicity, with pro-WMR being less toxic than the active peptide. Previously, host toxicity issues have hampered the clinical application of AMPs. However, the development of application-specific AMPs with modifications that minimize toxicity similar to those described here can significantly advance their potential use in patients. The combination of this prodrug strategy with a highly active AMP has the potential to produce new therapeutics for the challenging conditions of the CF patient lung.


Medicine and Health Sciences


Forde É, Schütte A, Reeves 3, Greene C, Humphreys H, Mall M, Fitzgerald-Hughes D, Devocelle M. Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis. Antimicrobial agents and chemotherapy.2016;60(5):2813-21.

PubMed ID


DOI Link


Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.